An international study to standardize the detection and quantitation of BCR-ABL transcripts from stabilized peripheral blood preparations by quantitative RT-PCR

被引:37
作者
Mueller, Martin C. [1 ]
Saglio, Guiseppe [2 ]
Lin, Feng [3 ]
Pfeifer, Heike [4 ]
Press, Richard D. [5 ]
Tubbs, Raymond R. [6 ]
Paschka, Peter [1 ]
Gottardi, Enrico [2 ]
O'Brien, Steven G.
Ottmann, Oliver G. [4 ]
Stockinger, Hubertus [7 ]
Wieczorek, Lothar
Merx, Kirsten [1 ]
Koenig, Heiko [1 ]
Schwindel, Uwe [1 ]
Hehlmann, Rudiger [1 ]
Hochhaus, Andreas [1 ]
机构
[1] Heidelberg Univ, Med Fak Mannheim, Med Univ Klin 3, Wiesbadener Str 7-11, D-68305 Mannheim, Germany
[2] Azienda Osped S Luigi Gonzaga, Orbassano, Italy
[3] Univ Newcastle, Sch Clin & Lab Sci, Newcastle Upon Tyne, Tyne & Wear, England
[4] Goethe Univ Frankfurt, Med Klin 2, Frankfurt, Germany
[5] Oregon Hlth & Sci Univ, Dept Pathol, Portland, OR 97201 USA
[6] Cleveland Clin, Lerner Coll Med, Dept Clin Pathol, Cleveland, OH 44106 USA
[7] Roche Diagnost, Penzberg, Germany
关键词
standardization; quantitative PCR; BCR-ABL; chronic myelogenous leukemia;
D O I
10.3324/haematol.11172
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Due to the lack of comparability of BCR-ABL mRNA quantification results generated by various methodologies in different laboratories, an international multicenter trial was started with the participation of six laboratories (platforms: LightCycler (TM), LC, n=3; TaqMan (TM), TM, n=3). One hundred and eighty-six PB samples derived from healthy donors were spiked with serial dilutions (1:20 to 1:2x10(6)) of b2a2, b3a2 or e1a2 BCR-ABL positive white blood cells (WBC) from leukemic patients. After PAXgene (TM) stabilization, blinding, freezing and distribution, standardized RNA extraction, cDNA synthesis, PCR protocols and data evaluation were carried out. There was no significant difference in the results achieved using LC and TM technologies, but a considerable overall variation (CV=0.74 for ratios BCR-ABL/ABL). Up to a dilution of 1:1,000, 27/30 of the 2.5 mL samples tested positive. For higher dilutions, a PB volume of 5 or 10 ml was required to improve sensitivity. The study showed the feasibility of RQ-PCR standardization independent of the PCR machine used.
引用
收藏
页码:970 / 973
页数:4
相关论文
共 13 条
  • [1] Molecular responses in patients with chronic myelogenous leukemia in chronic phase treated with imatinib mesylate
    Cortes, J
    Talpaz, M
    O'Brien, S
    Jones, D
    Luthra, R
    Shan, J
    Giles, F
    Faderl, S
    Verstovsek, S
    Garcia-Manero, G
    Rios, MB
    Kantarjian, H
    [J]. CLINICAL CANCER RESEARCH, 2005, 11 (09) : 3425 - 3432
  • [2] CROSS NCP, 1993, BLOOD, V82, P1929
  • [3] Comparison of two standardisation methods in real-time quantitative RT-PCR to follow Staphylococcus aureus genes expression during in vitro growth
    Eleaume, H
    Jabbouri, S
    [J]. JOURNAL OF MICROBIOLOGICAL METHODS, 2004, 59 (03) : 363 - 370
  • [4] Standardization and quality control studies of 'real-time' quantitative reverse transcriptase polymerase chain reaction of fusion gene transcripts for residual disease detection in leukemia -: A Europe Against Cancer Program
    Gabert, J
    Beillard, E
    van der Velden, VHJ
    Bi, W
    Grimwade, D
    Pallisgaard, N
    Barbany, G
    Cazzaniga, G
    Cayuela, JM
    Cavé, H
    Pane, F
    Aerts, JLE
    De Micheli, D
    Thirion, X
    Pradel, V
    González, M
    Viehmann, S
    Malec, M
    Saglio, G
    van Dongen, JJM
    [J]. LEUKEMIA, 2003, 17 (12) : 2318 - 2357
  • [5] Hochhaus A, 2000, BLOOD, V95, P62
  • [6] Quantification of residual disease in chronic myelogenous leukemia patients on interferon-alpha therapy by competitive polymerase chain reaction
    Hochhaus, A
    Lin, F
    Reiter, A
    Skladny, H
    Mason, PJ
    vanRhee, F
    Shepherd, PCA
    Allan, NC
    Hehlmann, R
    Goldman, JM
    Cross, NCP
    [J]. BLOOD, 1996, 87 (04) : 1549 - 1555
  • [7] Frequency of major molecular responses to imatinib or interferon alfa plus cytarabine in newly diagnosed chronic myeloid leukemia
    Hughes, TP
    Kaeda, J
    Branford, S
    Rudzki, Z
    Hochhaus, A
    Hensley, ML
    Gathmann, I
    Bolton, AE
    van Hoomissen, IC
    Goldman, JM
    Radich, JP
    Taylor, K
    Durrant, S
    Schwarer, A
    Joske, D
    Seymour, J
    Grigg, A
    Ma, D
    Arthur, C
    Bradstock, K
    Joshua, D
    Lechner, K
    Verhoef, G
    Louwagie, A
    Martiat, P
    Straetmans, N
    Bosly, A
    Shepherd, J
    Shustik, C
    Lipton, J
    Kovacs, DM
    Turner, AR
    Nielsen, JL
    Birgens, H
    Bjerrum, OW
    Guilhot, F
    Reiffers, J
    Rousselot, P
    Facon, T
    Harousseau, JL
    Tulliez, M
    Guerci, A
    Blaise, D
    Maloisel, F
    Michallet, M
    Fischer, T
    Hossfeld, D
    Mertelsmann, R
    Andreesen, R
    Nerl, C
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2003, 349 (15) : 1423 - 1432
  • [8] Hughes TP, 2006, BLOOD
  • [9] Application of a commercial kit for detection of PCR products to quantification of human immunodeficiency virus type 1 RNA and proviral DNA
    Lin, HJ
    Haywood, M
    Hollinger, FB
    [J]. JOURNAL OF CLINICAL MICROBIOLOGY, 1996, 34 (02) : 329 - 333
  • [10] Early reduction of BCR-ABL mRNA transcript levels predicts cytogenetic response in chronic phase CML patients treated with imatinib after failure of interferon α
    Merx, K
    Müller, MC
    Kreil, S
    Lahaye, T
    Paschka, P
    Schoch, C
    Weisser, A
    Kuhn, C
    Berger, U
    Gschaidmeier, H
    Hehlmann, R
    Hochhaus, A
    [J]. LEUKEMIA, 2002, 16 (09) : 1579 - 1583